Strip out the Covid product gains and Pfizer’s predicament is unchanged. It is struggling to convince investors there is life ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

Pfizer (NYSE:PFE) shares climbed around 2% in premarket trading Tuesday after the pharma giant raised earnings and revenue ...

Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance(1) ...